708273-57-8

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone is used as a pharmaceutical compound for its potential medicinal properties. It is under research for its anti-inflammatory and antioxidant effects, which could contribute to the development of new treatments for various conditions.
Used in Neurodegenerative Disease Treatment:
In the field of neurology, 4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone is being studied for its potential application in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Its capacity to target specific pathways involved in these diseases makes it a valuable asset in the search for effective therapeutic interventions.
Used in Drug Development:
4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone is utilized as a target in drug development due to its unique chemical structure and the possibility of modulating its properties to enhance therapeutic effects. Researchers are exploring its potential to be modified or combined with other compounds to create novel drugs with improved efficacy and safety profiles.

InChI:InChI=1/C12H15NO3/c1-16-11-3-2-9(8-13-11)12(15)6-4-10(14)5-7-12/h2-3,8,15H,4-7H2,1H3

Upstream product

• 13472-85-0 2-methoxy-5-bromopyridine 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 708273-56-7 8-(6-methoxy-pyridin-3-yl)-1,4-dioxa-spiro[4.5]decan-8-ol 

Downstream Products

• 1161428-49-4 (1-(4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl)-3-(methoxymethyl)pyrrolidin-3-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone 
• 887401-92-5 INCB₃₂₈₄ 
• 887401-93-6 N-(2-((R)-1-(trans-4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide bismethanesulfonate 
• 1401993-39-2 8-[4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl]-3-methyl-4-{[7-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1-oxa-8-azaspiro[4.5]dec-3-en-2-one 
• 1252689-15-8 4-(6-Methoxy-pyridin-3-yl)-cyclohex-3-enone 

Relevant academic research and scientific papers

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 antagonist as a development candidate

We have discovered a novel series of 4-Azetidinyl-1-Aryl-cyclohexanes as CCR2 antagonists. Divergent SAR studies on hCCR2 and hERG activities led to the discovery of compound 8d, which displayed good hCCR2 binding affinity (IC 50, 37 nM) and po

CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist

We report the identification of 13 (INCB3284) as a potent human CCR2 (hCCR2) antagonist. INCB3284 exhibited an IC50 of 3.7 nM in antagonism of monocyte chemoattractant protein-1 binding to hCCR2, an IC 50 of 4.7 nM in antagonism of c

4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).

4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).